DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

4 week cycles

DRUG

Fulvestrant

4 week cycles

DRUG

Adjuvant Therapy

Standard of Care

Trial Locations (19)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

11794

RECRUITING

Stony Brook University Cancer Center, Stony Brook

23229

RECRUITING

Virginia Cancer Institute, Richmond

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

43210

RECRUITING

The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus

53792

RECRUITING

University of Wisconsin Clinical Science Center, Madison

68516

RECRUITING

Cancer Partners of Nebraska, Lincoln

70112

RECRUITING

Louisiana State University Health Sciences Center- New Orleans, New Orleans

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

78041

RECRUITING

PRiSMs Group, Laredo

80045

RECRUITING

University of Colorado Cancer Center, Aurora

80401

RECRUITING

Intermountain, Golden

85724

RECRUITING

University of Arizona Cancer Center, Tucson

87131

RECRUITING

New Mexico Cancer Care Alliance, Albuquerque

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

90048

COMPLETED

Cedars-Sinai Medical Center, Los Angeles

97239

RECRUITING

Oregon Health and Science University, Portland

98104

RECRUITING

Swedish Cancer Institute, Seattle

06510

RECRUITING

Yale Cancer Center, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Criterium, Inc.

INDUSTRY

NCT04567420 - DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) | Biotech Hunter | Biotech Hunter